New triple therapy shows promise for aggressive lung cancer
NCT ID NCT05092412
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment for people with extensive-stage small cell lung cancer, a fast-growing type of lung cancer that has spread. The treatment combined low-dose radiation, an immunotherapy drug (durvalumab), and standard chemotherapy. The goal was to see if this combination could help control the cancer longer. The study enrolled 30 adults and is no longer recruiting new participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DURVALUMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
West China Hospital Sichuan University
Chengdu, Sichuan, 610044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection